а обращения: 28.01.2021).
239. Zheng S.L., Roddick A.J., Aghar-Jaffar R. et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018 Apr 17;319(15):1580–1591. doi: 10.1001/jama.2018.3024. www.ncbi.nlm.nih.gov/pubmed/29677303 (дата обращения: 28.01.2021).
240. Mannucci E., Dicembrini I., Nreu B., Monami M. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials. Diabetes Obes Metab. 2020 Feb;22(2):203–211. doi: 10.1111/dom.13888. www.ncbi. nlm.nih.gov/pubmed/31595657 (дата обращения: 28.01.2021).
241. Gerstein H.C., Colhoun H.M., Dagenais G.R. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121–130. doi: 10.1016/S0140-6736(19)31149-3. www.ncbi.nlm.nih.gov/pubmed/31189511 (дата обращения: 28.01.2021).
242. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest. 2003 Jun;111(12):1805-12. doi: 10.1172/JCI18921. www.ncbi.nlm.nih.gov/ pubmed/12813013 (дата обращения: 28.01.2021).
243. McNeill E., Channon K.M., Greaves D.R. Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. Clin Sci (Lond). 2010 Mar 9;118(11):641-55. doi: 10.1042/CS20090488. www.ncbi.nlm.nih. gov/pubmed/20210786 (дата обращения: 28.01.2021).
244. Eastwood J.A., Taylor D.A., Johnson B.D. et al. Premature atherosclerosis in premenopausal women: Does cytokine balance play a role? Med Hypotheses. 2017 Nov;109:38–41. doi: 10.1016/j.mehy.2017.09.010. www.ncbi.nlm.nih.gov/ pubmed/29150290 (дата обращения: 28.01.2021).
245. Singh T., Newman A.B. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011 Jul;10(3):319-29. doi: 10.1016/j.arr.2010.11.002. www.ncbi.nlm. nih.gov/pubmed/21145432 (дата обращения: 28.01.2021).
246. Tang Y., Fung E., Xu A., Lan H.Y. C-reactive protein and ageing. Clin Exp Pharmacol Physiol. 2017 Dec;44 Suppl 1:9-14. doi: 10.1111/1440-1681.12758. www. ncbi.nlm.nih.gov/pubmed/28378496 (дата обращения: 28.01.2021).
247. Payne G.W. Effect of inflammation on the aging microcirculation: impact on skeletal muscle blood flow control. Microcirculation. 2006 Jun; 13(4):343-52. doi: 10.1080/10739680600618918. www.ncbi.nlm.nih.gov/pubmed/16611596 (дата обращения: 28.01.2021).
248. Torzewski J., Torzewski M., Bowyer D.E. et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1386-92. doi: 10.1161/01.atv.18.9.1386. www.ncbi.nlm.nih.gov/pubmed/9743226 (дата обращения: 28.01.2021).
249. High-sensitivity C-reactive Protein (hs-CRP). (Электронный ресурс) URL: https://labtestsonline.org/tests/high-sensitivity-c-reactive-protein-hs-crp (дата обращения: 28.01.2021).
250. Hussein A.A., Gottdiener J.S., Bartz T.M. et al. Inflammation and sudden cardiac death in a community-based population of older adults: the Cardiovascular Health Study. Heart Rhythm. 2013 Oct;10(10):1425-32. doi: 10.1016/j.hrthm.2013.07.004. www.ncbi. nlm.nih.gov/pubmed/23906927 (дата обращения: 28.01.2021).
251. Puzianowska-Ku nicka M., Owczarz M., Wieczorowska-Tobis K. et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. Immun Ageing. 2016 Jun 3;13:21. doi: 10.1186/s12979-016-0076-x. www.ncbi.nlm.nih.gov/ pubmed/27274758 (дата обращения: 28.01.2021).
252. Pletnikoff P.P., Laukkanen J.A., Tuomainen T.P. et al. Cardiorespiratory fitness, C-reactive protein and lung cancer risk: A prospective population-based cohort study. Eur J Cancer. 2015 Jul;51(11):1365-70. doi: 10.1016/j.ejca.2015.04.020. www.ncbi.nlm. nih.gov/pubmed/26008754 (дата обращения: 28.01.2021).
253. Allin K.H., Nordestgaard B.G. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. Jul-Aug 2011;48(4):155-70. doi: 10.3109/10408363.2011.599831. www.ncbi.nlm.nih.gov/pubmed/22035340 (дата обращения: 28.01.2021).
254. Berk M., Williams L.J., Jacka F.N. et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013 Sep 12;11:200. doi: 10.1186/1741-7015-11-200. www.ncbi.nlm.nih.gov/pubmed/24228900 (дата обращения: 28.01.2021).
255. Ridker P.M., Danielson E., Fonseca F.A. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. www.ncbi.nlm.nih.gov/ pubmed/18997196 (дата обращения: 28.01.2021).
256. Bell G.A., Kantor E.D., Lampe J.W. et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012 Aug;27(8):593–603. doi: 10.1007/s10654-012-9714-6. www.ncbi.nlm.nih.gov/pubmed/22828954 (дата обращения: 28.01.2021).
257. Navarro S.L., White E., Kantor E.D. et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015 Feb 26;10(2):e0117534. doi: 10.1371/journal.pone.0117534. www.ncbi.nlm.nih.gov/pubmed/25719429 (дата обращения: 29.01.2021).
258. Esfandiari H., Pakravan M., Zakeri Z. et al. Effect of glucosamine on intraocular pressure: a randomized clinical trial. Eye (Lond). 2017 Mar;31(3):389–394. doi: 10.1038/ eye.2016.221. www.ncbi.nlm.nih.gov/m/pubmed/27768119 (дата обращения: 29.01.2021).
259. Tom s Abadal L., Varas Lorenzo C., P rez I. et al. [Risk factors and coronary morbimortality in a Mediterranean industrial cohort over 28 years of follow-up. The Manresa Study]. Rev Esp Cardiol. 2001 Oct;54(10):1146-54. doi: 10.1016/s0300-8932(01)76472-x. [Article in Spanish] www.ncbi.nlm.nih.gov/pubmed/11591294 (дата обращения: 29.01.2021).
260. [No authors listed.] Classics in arteriosclerosis research: On experimental cholesterin steatosis and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, translated by Mary Z. Pelias, 1913. Arteriosclerosis. Mar-Apr 1983;3(2):178-82. www.ncbi.nlm.nih.gov/pubmed/6340651 (дата обращения: 29.01.2021).
261. Berger S., Raman G., Vishwanathan R. et al. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2015 Aug;102(2):276-94. doi: 10.3945/ajcn.114.100305. www.ncbi.nlm.nih.gov/pubmed/26109578 (дата обращения: 29.01.2021).
262. Eenfeldt A. Stunning: Saturated fat and the European paradox. June 17 2012. (Электронный ресурс) URL: www.dietdoctor.com/stunning-saturated-fat-and-the-european-paradox (дата обращения: 29.01.2021).
263. Hoenselaar R. Further response from Hoenselaar. Br J Nutr. 2012 Sep;108(5):939-42. doi: 10.1017/S0007114512000402. www.ncbi.nlm.nih.gov/ pubmed/22377374 (дата обращения: 29.01.2021).
264. Chowdhury R., Warnakula S., Kunutsor S. et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med. 2014 Mar 18;160(6):398–406. doi: 10.7326/M13-1788. www.ncbi. nlm.nih.gov/pubmed/24723079 (дата обращения: 29.01.2021).
265. Puaschitz N.G., Strand E., Norekval T.M. et al. Dietary intake of saturated fat is not associated with risk of coronary events or mortality in patients with established coronary artery disease. J Nutr. 2015 Feb;145(2):299–305. doi: 10.3945/jn.114.203505. www.ncbi.nlm.nih.gov/pubmed/25644351 (дата обращения: 29.01.2021).
266. Pimpin L., Wu J.H., Haskelberg H. et al. Is Butter Back? A Systematic Review and Meta-Analysis of Butter Consumption and Risk of Cardiovascular Disease, Diabetes, and Total Mortality. PLoS One. 2016 Jun 29;11(6):e0158118. doi: 10.1371/ journal.pone.0158118. www.ncbi.nlm.nih.gov/pubmed/27355649 (дата обращения: 29.01.2021).
267. Your guide to Lowering your cholesterol with TLC. U.S. Department of health and human services, National Institutes of Health, National Heart, Lung, and Blood Institute; NIH Publication No. 06-5235 December 2005. (Электронный ресурс) URL: www.nhlbi.nih.gov/files/docs/public/heart/chol_tlc.pdf (дата обращения: 29.01.2021).
268. Shor R., Wainstein J., Oz D. et al. Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy. Ann Clin Lab Sci. Autumn 2007;37(4):343-8. www. ncbi.nlm.nih.gov/pubmed/18000291 (дата обращения: 29.01.2021).
269. Meng L., Jin W., Wang X. RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality. Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11007-12. doi: 10.1073/pnas.1514730112. www.ncbi.nlm.nih.gov/pubmed/26283397 (дата обращения: 29.01.2021).
270. Weverling-Rijnsburger A.W., Blauw G.J., Lagaay A.M. et al. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997 Oct 18;350(9085):1119-23. doi: 10.1016/s0140-6736(97)04430-9. www.ncbi.nlm.nih.gov/pubmed/9343498 (дата обращения: 29.01.2021).
271. DiNicolantonio J.J., McCarty M.F. Is interleukin-6 the link between low LDL cholesterol and increased non-cardiovascular mortality in the elderly? Open Heart. 2018 Apr 13;5(1):e000789. doi: 10.1136/openhrt-2018-000789. www.ncbi.nlm.nih. gov/pubmed/29682295 (дата обращения: 29.01.2021).
272. Таблица SCORE риска смерти от сердечно-сосудистого заболевания в ближайшие 10 лет для стран Европы с высоким риском. (Электронный ресурс) URL: https://commons.wikimedia.org/wiki/File: SCORE2007.png (дата обращения: 29.01.2021).
273. Roitelman J. Olender E.H. Bar-Nun S. et al. Immunological evidence for eight spans in the membrane domain of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for enzyme degradation in the endoplasmic reticulum. J Cell Biol. 1992 Jun; 117(5):959-73. doi: 10.1083/jcb.117.5.959. www.ncbi.nlm.nih.gov/pubmed/1374417 (дата обращения: 29.01.2021).